Serial entrepreneur. Since 2010, he has been involved in the management of three companies in the biotechnology industry. He served as the founding CEO of two of these companies (Cyfuse Biomedical (TSE: 4892) and EXORPHIA) and as a Director and Executive Officer at the other (ReproCell (TSE:4978)). He founded EXORPHIA in May 2019 and assumed the position of President and CEO (current). He possesses extensive experience in founding and managing R&D-focused ventures.
Prior to the biotech industry, he engaged in the development of mobile devices at Panasonic, patent application work at a patent law firm, and formulating management strategies and operational reforms for manufacturing industries at McKinsey & Company. He graduated from Keio University, Faculty of Science and Technology.

After serving as a partner at Hasegawa Toshiaki Law Office and Squire Sanders Foreign Law Joint Enterprise (currently Squire Foreign Law Joint Enterprise), he established Matsumoto Munehiro Law Office in 2013, where he currently serves as the representative attorney. He graduated from the Faculty of Law at the University of Tokyo and received his LL.M. from the University of Pennsylvania Law School in the United States.

He engaged in consulting for the pharmaceutical and medical device sectors at McKinsey & Company. He was a postdoctoral fellow at the Institute for Integrated Cell-Material Sciences (iCeMS) at Kyoto University. He obtained his Ph.D. in stem cell biology and molecular biology from the Institute of Molecular and Cellular Biosciences at the University of Tokyo.

At Sumitomo Corporation Pharma International Co., Ltd., he was involved in managing venture capital funds, investing in biotech ventures, and serving as a domestic sales representative for overseas biotech ventures. He has been in his current position since 2016. He completed his graduate studies at the Graduate School of Engineering, Nagoya University, where he obtained a doctoral degree in biochemical engineering.

At Ohta Showa Audit Corporation (currently Ernst & Young ShinNihon LLC), he was in charge of auditing major chemical manufacturers and supported numerous IPOs. After working on supporting the growth of university-based ventures, he became independent in July 2019 and established EDiX Professional Group Edogawa CPA Office, where he currently serves as the representative partner. He graduated from the Faculty of Law, Department of Law, at Keio University.

Serial entrepreneur. Since 2010, he has been involved in the management of three companies in the biotechnology industry. He served as the founding CEO of two of these companies (Cyfuse Biomedical (TSE: 4892) and EXORPHIA) and as a Director and Executive Officer at the other (ReproCell (TSE:4978)). He founded EXORPHIA in May 2019 and assumed the position of President and CEO (current). He possesses extensive experience in founding and managing R&D-focused ventures.
Prior to the biotech industry, he engaged in the development of mobile devices at Panasonic, patent application work at a patent law firm, and formulating management strategies and operational reforms for manufacturing industries at McKinsey & Company. He graduated from Keio University, Faculty of Science and Technology.

A founding member of EXORPHIA, Inc. After completing her doctoral course in Medical Sciences at the Graduate School of Medicine, Tohoku University, she engaged in drug discovery research at TOYAMA CHEMICAL CO., LTD. (currently FUJIFILM Toyama Chemical Co., Ltd.) for 7 years. She then worked in medical affairs at Janssen Pharmaceuticals and MSD K.K. before leading the development of drug discovery research tools at a biotech venture. She holds a Doctor of Medicine degree and specializes in pharmacology (inflammation and immunity).

She has over 15 years of experience in clinical development at Allergan Japan and Genzyme Japan, where she served as a project leader. Her responsibilities included planning clinical development, designing and preparing clinical trial protocols, preparing materials for consultations with regulatory authorities and conducting discussions, as well as preparing new drug application materials and handling regulatory affairs related to approvals.
At Parexel International Inc., she led the Clinical Development Department as the Head of Clinical Development in Japan. Since 2021, she has been serving as the Representative Director of MedCham Co., Ltd., a consulting company for pharmaceutical development. She holds a Doctor of Pharmacy degree.

He completed his doctoral course in Health Sciences at the Graduate School of Medicine, Kobe University. With over 15 years of experience in drug discovery research at Takeda Rabics (currently Rabics) and Fujifilm, he then joined StemRIM Inc. (TSE: 4599), an Osaka University-originated biotech venture, where he led drug discovery research as the Head of the Pharmaceutical Research Department and Executive Officer while also being responsible for business development aimed at out-licensing. He joined EXORPHIA in 2023. He holds a Doctor of Health Sciences degree and an MBA.

He specializes in stem cell and designer cell development. After completing a master’s degree in Life Science and Biomedical Sciences at the Graduate School of Advanced Science and Engineering, Waseda University, he worked for 10 years in R&D of stem cell products and regulatory development of regenerative medicine products at ReproCELL, National Center for Child Health and Development, and other companies. He was also involved in the development of ISO standards for equivalence/identicality testing of regenerative medicine products. He completed his MBA at Bond University in Australia.